Arcus Biosciences (RCUS) Other Accumulated Expenses (2017 - 2026)

Arcus Biosciences' Other Accumulated Expenses history runs 10 years deep, the most recent figure standing at $136.0 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 38.78% year-over-year to $136.0 million; the TTM figure through Mar 2026 stood at $136.0 million (up 38.78% YoY), while the FY2025 annual figure was $154.0 million, up 25.2% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $136.0 million, down from $154.0 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $154.0 million in Q4 2025, with the low at $1.5 million in Q1 2022.
• The 5-year median for Other Accumulated Expenses is $76.0 million (2022), against an average of $78.5 million.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses sank 94.92% in 2022, then surged 3791.05% in 2023.
• Arcus Biosciences' Other Accumulated Expenses stood at $76.0 million in 2022, then changed by 0.0% to $76.0 million in 2023, then jumped by 61.84% to $123.0 million in 2024, then rose by 25.2% to $154.0 million in 2025, then retreated by 11.69% to $136.0 million in 2026.
• Business Quant data shows RCUS's Other Accumulated Expenses at $136.0 million in Q1 2026, $154.0 million in Q4 2025, and $141.0 million in Q3 2025.